PAXIL (paroxetine hydrochloride) by Aurobindo Pharma is 12. First approved in 1997.
Drug data last refreshed Yesterday
12.1 Mechanism of Action The mechanism of action of PAXIL in the treatment of MDD, SAD, OCD, PD, GAD, and PTSD is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin…
Worked on PAXIL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)
Paxil CR Bioequivalence Study Brazil - Fed Administration
Paxil CR Bioequivalence Study Brazil
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)